CELESTONE (betamethasone sodium phosphate) by Merck & Co. is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dry eye disease. First approved in 1974.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
CELESTONE is a synthetic glucocorticoid (betamethasone sodium phosphate) administered by injection for the treatment of dry eye disease. It works through anti-inflammatory mechanisms by reducing ocular inflammation and suppressing immune responses that contribute to tear deficiency. The sodium phosphate ester formulation provides prompt activity, making it suitable for acute intervention in inflammatory dry eye conditions.
As an aging product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely consolidating and preparing for generic transition, signaling potential staffing reductions or shift toward managed care roles.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Worked on CELESTONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CELESTONE offers limited growth trajectory as the product approaches and enters loss of exclusivity; roles are primarily defensive, focused on managed care negotiations, cost containment, and preventing share erosion to newer competitors. Career advancement is constrained by the product's mature lifecycle and lack of innovation pipeline.